Everest Medicines Revenue

Everest Medicines had revenue of 446.12M CNY in the half year ending June 30, 2025, with 4,915.44% growth. This brings the company's revenue in the last twelve months to 851.28M, up 103.39% year-over-year. In the year 2024, Everest Medicines had annual revenue of 706.68M with 461.16% growth.

Revenue (ttm)

851.28M CNY

Revenue Growth

+103.39%

P/S Ratio

13.48

Revenue / Employee

1.18M CNY

Employees

722

Market Cap

12.58B HKD

Revenue Chart

* This company reports financials in CNY.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	706.68M	580.75M	461.16%
Dec 31, 2023	125.93M	113.14M	884.46%
Dec 31, 2022	12.79M	12.74M	23,588.89%
Dec 31, 2021	54.00K	-	-
Dec 31, 2020	-	-	-
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Ascletis Pharma	2.59M
Keymed Biosciences	955.73M
HBM Holdings	908.35M
Shanghai Haohai Biological Technology	2.75B
CStone Pharmaceuticals	221.89M
Ascentage Pharma Group International	428.02M
Zai Lab	3.58B
Abbisko Cayman	681.17M

Revenue Rankings

Everest Medicines News

4 weeks ago - Everest Medicines Advances With Major Licensing Deal, New Drug Application Approval - Benzinga
1 year ago - AI-powered Cancer Vaccine In The Works - Benzinga
1 year ago - Kezar Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Benzinga

More News